The difference in the pCR rate between our present study and that prior Indian report may also have been due to differences in the proportion of triple negative breast cancers (TNBCs) and HER2-positive tumors, even though they have a similar clinical stage (Neo-Shorter vs. India, 32.4% vs. 49%). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.